Parexel Ponders Acquisitions
This article was originally published in The Pink Sheet Daily
Executive Summary
Parexel is considering a strategic acquisition as it looks to utilize more than $100 mil. in excess cash
You may also be interested in...
Parexel’s Yen For Expansion Yields Acquisition Of Japanese Bridging Study Experts
Deal worth $60 mil. could bring in business from firms seeking drug approval in Japan.
Parexel’s Yen For Expansion Yields Acquisition Of Japanese Bridging Study Experts
Deal worth $60 mil. could bring in business from firms seeking drug approval in Japan.
Parexel Gets Boost From Small-Firm Contracts
Parexel experiences an increased level of business from smaller divisions or standalone companies that are "embracing a more strategic way of outsourcing," CEO Rickenbach said. The contract research organization also saw an increase in later stage trials, including "healthy" demand for Phase IV studies.